Budesonide/formoterol - Intech Biopharm

Drug Profile

Budesonide/formoterol - Intech Biopharm

Alternative Names: SYN 010; SYN010 HFA Inhaler

Latest Information Update: 19 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intech Biopharm
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Aug 2016 Chemical structure information added
  • 08 Aug 2016 Intech Biopharm plans a clinical trial for Asthma and Chronic obstructive pulmonary disease in Countries worldwide (Intech Biopharm website, August 2016)
  • 31 May 2016 Intech Biopharm completes a phase I trial in Asthma and Chronic obstructive pulmonary disease (In healthy volunteers) in Taiwan (Inhalation) (NCT02850484)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top